Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Stat3 is required for the development of skin cancer
Laura Pedranzini, … , Andrea Leitch, Jacqueline Bromberg
Laura Pedranzini, … , Andrea Leitch, Jacqueline Bromberg
Published September 1, 2004
Citation Information: J Clin Invest. 2004;114(5):619-622. https://doi.org/10.1172/JCI22800.
View: Text | PDF
Commentary

Stat3 is required for the development of skin cancer

  • Text
  • PDF
Abstract

Signal transducer and activator of transcription 3 (Stat3) is a transcription factor that is constitutively activated in a variety of human malignancies, including prostate, lung, brain, breast, and squamous cell carcinomas. Inhibition of activated Stat3 leads to decreased proliferation and apoptosis of many cancer-derived cell lines, while the introduction of a constitutively activated form of Stat3 into immortalized human breast epithelial cells and rodent fibroblasts results in cellular transformation. Collectively, these data suggest a role for Stat3 in oncogenesis. A new study from Chan et al. (see related article beginning on page 720) is the first to demonstrate a requirement for Stat3 in de novo epithelial carcinogenesis in vivo. Using the two-step model of chemically induced skin carcinogenesis, the authors demonstrated that mice deficient in Stat3 were completely resistant to skin tumor development.

Authors

Laura Pedranzini, Andrea Leitch, Jacqueline Bromberg

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Two-step model of chemically induced carcinogenesis and proposed role of...
Two-step model of chemically induced carcinogenesis and proposed role of Stat3 in preventing tumorigenesis. Initiation is achieved by topical application of the carcinogen DMBA, which binds to DNA and typically induces mutations in the Ha-ras gene. The result of this process is the formation of an initiated cell. During this stage Stat3 protects the keratinocytes and the initiated cells from DNA damage–induced apoptosis. Promotion involves repeated application of a noncarcinogenic promoter, TPA, leading to clonal expansion of the initiated cell. This process results in the formation of multiple benign papillomas. Stat3 is essential for the proliferation of the initiated cells after TPA treatment and for the maintenance of the preoncogenic lesions. Progression is a spontaneous process characterized by the accumulation of additional genetic changes (i.e., elevated expression of genes encoding Ha-ras and cyclin D1; loss of functional p53), which accelerate the conversion of benign papillomas to malignant carcinomas. The pink cells represent initiated cells bearing Ha-ras mutations; the purple cells represent cells that have acquired multiple genetic changes.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts